Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

Curtis A Lachowiez; Vishvaas I Ravikumar; Jad Othman; Jenny O'Nions; Daniel T Peters; Christine McMahon; Ronan Swords; Rachel Cook; Jennifer N Saultz; Jeffrey W Tyner; Richard James Dillon; Joshua F Zeidner; Daniel A Pollyea

doi:10.1182/blood.2024026925

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

Blood. 2024 Nov 1:blood.2024026925. doi: 10.1182/blood.2024026925. Online ahead of print.

Authors

Affiliations

¹ Oregon Health & Science University, Portland, Oregon, United States.
² Kings College London, London, United Kingdom.
³ University College London Hospitals NHS Foundation Trust, London, United Kingdom.
⁴ University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States.
⁵ University of Colorado, Aurora, Colorado, United States.
⁶ OHSU Knight Cancer Institute Center for Hematologic Malignancies, Portland, Oregon, United States.
⁷ OHSU Knight Cancer Institute, Portland, Oregon, United States.
⁸ Division of hematology/medical oncology, Oregon Health & Science University, Portland, Oregon, United States.
⁹ Oregon Health & Science University School of Medicine, Portland, Oregon, United States.
¹⁰ King's College, London, London, United Kingdom.
¹¹ University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States.

PMID: 39486083
DOI: 10.1182/blood.2024026925

Abstract

The ELN 2024 risk-stratification guidelines for patients with acute myeloid leukemia receiving hypomethylating agents combined with venetoclax were recently published. This analysis demonstrates re-classification and incorporation of new gene mutations in the present model can further improve and individualize prognostication.